Kelly Qiao is a Senior Principal at B Capital, where she leads healthcare investments across Asia. She focuses on opportunities in biotech, medtech and digital health.

Since joining B Capital, Kelly has invested in and serves on the boards of Insilico Medicine, ProfoundBio (acquired by Genmab), Grit Biotechnology, Rona Therapeutics, Vivacta Bio, Spectrumedics Medical, Macrolux Medical, and AlphaLife Sciences. She has also invested in MediTrust Health and Yuanxin Technology.

Prior to joining B Capital, Kelly built over a decade of experience across healthcare investing and operations. She previously worked as Managing Director for global healthcare investment at Fosun (656.HK). Prior to that, Kelly served as an Executive Director at Vertex Ventures, where she invested in Chipscreen Biosciences (688321.SH) and Phoenix Healthcare Group (1515.HK), and served on the Board of Chipscreen. She also worked in drug discovery at GlaxoSmithKline and sales and marketing at Roche.

Kelly holds a PhD in Biology and a BSc in Chemistry from Tsinghua University and an MBA in Finance from The Chinese University of Hong Kong.